Latest On Evotec SE (EVTCY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-10-27 09:59 EST | News | Evotec launches 22M in ADSs offering in U.S. | N/A |  |
| 2021-08-12 09:15 EST | News | Evotec SE (EVOTF) CEO Werner Lanthaler on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-11 13:38 EST | News | Evotec SE reports 1H results | N/A | |
| 2021-08-11 13:38 EST | News | Evotec SE 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-03-26 20:33 EST | News | Evotec SE 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-03-26 01:59 EST | News | Evotec SE (EVOTF) CEO Werner Lanthaler on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-01-28 17:48 EST | News | Evotec's early-stage trial of EVT894 to treat chikungunya virus kicks off | N/A | |
| 2021-01-05 09:28 EST | News | Evotec earns $6 milestone under neurodegeneration deal with Bristol Myers | N/A | |
| 2020-12-17 10:50 EST | News | Evotec achieves milestones in Bristol Myers pact in targeted protein degradation | N/A | |
| 2020-11-26 23:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-15 06:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-14 17:56 EST | News | Evotec SE (EVOTF) CEO Werner Lanthaler on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-12 12:55 EST | News | Evotec SE 2020 Q3 - Results - Earnings Call Presentation | N/A | |
| 2020-11-08 02:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-19 01:39 EST | News | Evotec (EVTCY) Presents At Morgan Stanley Annual Global Healthcare Conference - Slideshow | N/A | |
| 2020-09-19 01:39 EST | News | Evotec (EVTCY) Presents at H.C. Wainwright Annual Global Investment Conference - Slideshow | N/A | |
| 2020-09-17 08:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-15 06:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-13 07:10 EST | News | Evotec SE 2020 Q2 - Results - Earnings Call Presentation | N/A | |
| 2020-08-13 07:10 EST | News | Evotec SE's (EVOTF) CEO Werner Lanthaler on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-06 15:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 17:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 11:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 07:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 07:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 22:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 03:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-20 14:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-16 06:47 EST | News | Evotec SE reports Q1 results | N/A | |
| 2020-05-16 06:46 EST | News | Evotec's (EVOTF) CEO Werner Lanthaler on Q1 2020 Results - Earnings Call Transcript | N/A | |
| 2020-05-06 08:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 22:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-14 17:30 EST | News | Evotec SE reports FY results | N/A | |
| 2020-04-14 17:27 EST | News | Evotec inks deal with and Takeda for gene therapy programs | N/A | |
| 2020-04-09 22:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-07 14:48 EST | Financials | Company financials have been released. | Neutral | |
About Evotec SE (EVTCY):
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. Its EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation and Related Sciences; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi and Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene and Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; strategic collaborations with Ildong Pharmaceutical Co., Ltd. and Chinook Therapeutics, Inc.; a drug discovery research collaboration with HitGen Inc.; a partnership with Rappta Therapeutics; and a partnership with Sartorius. The company was founded in 1993 and is headquartered in Hamburg, Germany.
General
- Name Evotec SE
- Symbol EVTCY
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 3,444
- Last Split Factor10000:5271
- Last Split Date2008-05-05
- Fiscal Year EndDecember
- IPO Date2008-05-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryLife Sciences Tools & Services
- Gic SubIndustryLife Sciences Tools & Services
- Web URLhttp://www.evotec.com
Valuation
- Trailing PE 72.84
- Forward PE 151.52
- Price/Sales (Trailing 12 Mt.) 9.18
- Price/Book (Most Recent Quarter) 10.21
- Enterprise Value Revenue 12.38
- Enterprise Value EBITDA 146.76
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin 3%
- Return on Assets 3%
- Return on Equity 3%
- Earnings Per Share $0.98
- Revenue Per Share $0
- Gross Profit 132.89 million
- Quarterly Earnings Growth 13.3%
Highlights
- Market Capitalization 5.74 billion
- Book Value Per Share $6.16
Share Statistics
- Shares Outstanding 81.75 million
- Shares Float 57.92 million
- % Held by Insiders <1%
- Shares Short 12163
- Shares Short Prior Month 12718
- Short Ratio 0.62
Technicals
- Beta 0.81
- 52 Week High $90.14
- 52 Week Low $40.42
- 50 Day Moving Average 78.46
- 200 Day Moving Average 64.86
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Evotec SE (EVTCY) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Evotec SE (EVTCY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-12 | $N/A | -$0.02 | ||
| 2020-06-30 | 2020-09-30 | $N/A | -$0.01 | ||
| 2020-03-31 | 2020-06-30 | $119.4 million | -$0.07 | ||
| 2019-12-31 | 2020-03-31 | $125.08 million | $0.12 | ||
| 2019-09-30 | 2019-12-31 | $124.55 million | $0.06 | ||
| 2019-06-30 | 2019-09-30 | $116.51 million | $0.14 | ||
| 2019-03-31 | 2019-06-30 | $116.45 million | -$0.02 | ||
| 2018-12-31 | 2019-03-31 | $120.89 million | $0.10 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $111.44 million | $0.23 | ||
| 2018-06-30 | 2018-09-30 | $110.3 million | $0.27 | ||
| 2018-03-31 | 2018-06-30 | $97.16 million | $0.11 | ||
| 2017-12-31 | 2018-03-31 | $123.22 million | $0.02 | ||
| 2017-09-30 | 2017-12-31 | $91.28 million | $0.08 | ||
| 2017-06-30 | 2017-09-30 | $71.72 million | $0.02 | ||
| 2017-03-31 | 2017-06-30 | $61.64 million | $0.02 | ||
| 2016-12-31 | 2017-03-31 | $46.98 million | $0.05 | ||
| 2016-09-30 | 2016-12-31 | $59.14 million | $0.11 | ||
| 2016-06-30 | 2016-09-30 | $47.78 million | $0.07 | ||
| 2016-03-31 | 2016-06-30 | $47.7 million | $0.03 | ||
| 2015-12-31 | 2016-03-31 | $45.12 million | -$0.01 | ||
| 2015-09-30 | 2015-12-31 | $41.04 million | $0.04 | ||
| 2015-06-30 | 2015-09-30 | $41.81 million | -$0.02 | ||
| 2015-03-31 | 2015-06-30 | $24.39 million | $0.12 | ||
| 2014-12-31 | 2015-03-31 | $37.82 million | -$0.01 | ||
| 2014-09-30 | 2014-12-31 | $20.12 million | $0.01 | ||
| 2014-06-30 | 2014-09-30 | $31.61 million | -$0.04 | ||
| 2014-03-31 | 2014-06-30 | $24.89 million | $-0.00 | ||
| 2013-12-31 | 2014-03-31 | $37.6 million | -$0.04 | ||
| 2013-09-30 | 2013-12-31 | $34.6 million | -$0.22 | ||
| 2013-06-30 | 2013-09-30 | $26.27 million | $-0.00 | ||
| 2013-03-31 | 2013-06-30 | $22.01 million | -$0.02 | ||
| 2012-12-31 | 2013-03-31 | $32.49 million | -$0.03 | ||
| 2012-09-30 | 2012-12-31 | $29.84 million | -$0.06 | ||
| 2012-06-30 | 2012-09-30 | $26.86 million | $0.06 | ||
| 2012-03-31 | 2012-06-30 | $27.13 million | $0.04 | ||
| 2011-12-31 | 2012-03-31 | $23.77 million | -$0.02 | ||
| 2011-09-30 | 2011-12-31 | $32.08 million | -$0.03 | ||
| 2011-06-30 | 2011-09-30 | $26.26 million | $0.09 | ||
| 2011-03-31 | 2011-06-30 | $23.69 million | $0.01 | ||
| 2010-12-31 | 2011-03-31 | $22.1 million | $-0.00 | ||
| 2010-09-30 | 2010-12-31 | $24.28 million | $0.03 | ||
| 2010-06-30 | 2010-08-12 | $18.43 million | $0.03 | ||
| 2010-03-31 | 2010-05-12 | $14.54 million | -$0.03 | ||
| 2009-12-31 | 2010-03-25 | $19.25 million | -$0.32 | ||
| 2009-09-30 | 2009-11-12 | $20.43 million | -$0.10 | ||
| 2009-06-30 | 2009-08-07 | $16.08 million | -$0.22 | ||
| 2009-03-31 | 2009-05-12 | $11.22 million | -$0.53 | ||
| 2008-12-31 | 2009-03-27 | $20.24 million | -$1.36 | ||
| 2008-09-30 | 2008-11-14 | $13.52 million | -$0.09 | ||
| 2008-06-30 | 2008-08-06 | $12.33 million | -$0.40 | ||
| 2008-03-31 | 2008-05-08 | $12.23 million | -$0.57 | ||
| 2007-03-31 | 2007-05-10 | $11.65 million | $0.11 | ||
| 2006-12-31 | 2007-03-29 | $15.57 million | -$0.64 | ||
| 2006-09-30 | 2006-11-09 | $13.72 million | -$0.18 | ||
| 2006-06-30 | 2006-08-11 | $24.26 million | -$0.04 | ||
| 2006-03-31 | 2006-05-11 | $N/A | -$0.40 | ||
| 2005-09-30 | 2005-11-09 | -$0.29 | |||
| 2005-06-30 | 2005-08-11 | -$1.32 | |||
| 2005-03-31 | 2005-05-10 | -$0.32 | |||
| 2004-12-31 | 2005-03-22 | -$4.75 | |||
| 2004-09-30 | 2004-11-11 | -$0.38 | |||
| 2004-06-30 | 2004-08-11 | -$0.38 | |||
| 2004-03-31 | 2004-05-12 | -$0.43 |
Evotec SE (EVTCY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 15.06 million | 17.15 million | 13.08 million |
| Income Before Tax | N/A | N/A | 18.87 million | 12.82 million | 27.03 million |
| Selling General Administrative | N/A | N/A | 17.25 million | 20.32 million | 17.79 million |
| Gross Profit | N/A | N/A | 33.27 million | 34.08 million | 38.16 million |
| Ebit | N/A | N/A | 21.62 million | 15.17 million | 24.4 million |
| Operating Income | N/A | N/A | 16.1 million | 16.17 million | 24.4 million |
| Income Tax Expense | 8.93 million | 2.77 million | N/A | 5.94 million | 6.27 million |
| Total Revenue | N/A | N/A | 119.4 million | 125.08 million | 124.55 million |
| Cost of Revenue | N/A | N/A | 86.13 million | 90.99 million | 86.39 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 2.63 million |
| Net Income From Continuing Operations | N/A | N/A | 17.08 million | 7.52 million | 20.76 million |
| Net Income Applicable to Common Shares | -1.41 million | -9.82 million | N/A | 9.37 million | 20.76 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -13.51 million | -28 million | -62.42 million |
| Change to Liabilities | N/A | N/A | N/A | -18.74 million | N/A |
| Total Cash Flow from Investing Activities | -29.7 million | -39.64 million | N/A | -31.39 million | -69.78 million |
| Net Borrowings | -3.11 million | 11.3 million | N/A | 15.35 million | -24.83 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | -24.14 million |
| Change to Operating Activities | 6.62 million | -44.39 million | N/A | 61.31 million | -24.6 million |
| Change in Cash | N/A | N/A | 10.02 million | 27.05 million | -79.17 million |
| Total Cash from Operating Activities | 27.76 million | -34.1 million | 27.13 million | 45.94 million | 13.3 million |
| Depreciation | N/A | N/A | N/A | N/A | 13.78 million |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 50.9 million | -8.25 million | N/A | 2.51 million | 3.36 million |
| Capital Expenditures | N/A | N/A | 16.34 million | 10.74 million | 6.48 million |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | 694.09 million | 703.88 million | 677.16 million |
| Total Stockholder Equity | N/A | N/A | 489.47 million | 477.03 million | 503.31 million |
| Other Current Liabilities | 121.81 million | N/A | 9.86 million | 12.85 million | 98.3 million |
| Total Assets | N/A | N/A | 1.18 billion | 1.18 billion | 1.18 billion |
| Common Stock | 151.9 million | 151.45 million | N/A | 169.19 million | 164.07 million |
| Other Current Assets | N/A | N/A | N/A | 3.82 million | N/A |
| Retained Earnings | -435.4 million | -433.88 million | -429.2 million | -441.18 million | -489.46 million |
| Other Liabilities | 76.29 million | 66.89 million | N/A | 92.57 million | 70.41 million |
| Other Assets | 66.46 million | 68.76 million | N/A | 65.02 million | 61.35 million |
| Cash | N/A | N/A | 285.41 million | 277.03 million | 272.06 million |
| Total Current Liabilities | 194.88 million | N/A | 185.04 million | 178.96 million | 145.87 million |
| Other Stockholder Equity | -34.43 million | -30.91 million | N/A | -21.93 million | -27.78 million |
| Property, Plant & Equipment | 270.29 million | 264.26 million | N/A | 266.84 million | 244.7 million |
| Total Current Assets | 427.19 million | N/A | 464.62 million | 469.53 million | 446.98 million |
| Long Term Investments | N/A | N/A | N/A | N/A | 33.11 million |
| Net Tangible Assets | 119.5 million | 117.76 million | N/A | 115.36 million | 108.07 million |
| Short Term Investments | N/A | N/A | 35.86 million | 44.63 million | 36.59 million |
| Long Term Debt | N/A | N/A | 324.44 million | 324.89 million | 344.73 million |
| Inventory | 11.69 million | N/A | 10.86 million | 10.75 million | 13.3 million |
| Accounts Payable | 44.14 million | N/A | 41.79 million | 31.32 million | 30.48 million |
Evotec SE (EVTCY) Chart:
Evotec SE (EVTCY) News:
Below you will find a list of latest news for Evotec SE (EVTCY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Evotec SE (EVTCY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Evotec SE (EVTCY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|